Skip to main content
. 2023 Mar 24;24(7):6111. doi: 10.3390/ijms24076111

Figure 3.

Figure 3

Blood cytokine levels at baseline in responders and non-responders to treatment with adalimumab or interleukin (IL)-17/IL-17R inhibitors. (A) Tumor necrosis factor (TNF)-α. (B) Soluble interleukin-6 signal transducer (sIL-6ST). (C) Interleukin-6 (IL-6). (D) Soluble interleukin-6 receptor (sIL-6R). Responders = psoriasis area and severity index (PASI) ≤ 2 three months after treatment start. Non-responders = PASI > 2 three months after treatment start. ns = non-significant. * p < 0.05.